Yahoo
Oslo - Delayed Quote NOK

Zelluna ASA (ZLNA.OL)

17.20 0.00 (0.00%)
At close: 4:25:17 PM GMT+1
Chart Range Bar
Loading chart for ZLNA.OL
  • Previous Close 17.20
  • Open 18.00
  • Bid 17.25 x --
  • Ask 17.60 x --
  • Day's Range 17.05 - 18.00
  • 52 Week Range 8.20 - 35.80
  • Volume 12,408
  • Avg. Volume 57,852
  • Market Cap (intraday) 513.601M
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -4.90
  • Earnings Date Nov 5, 2026
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est --

Zelluna ASA, a clinical-stage biotechnology company, engages in the development of T-cell receptor guided natural killer cell therapies in Norway. It develops ZI-MA4-1 which is in Phase I clinical trial for the treatment of non-small cell lung cancer, ovarian, and head and neck synovial sarcoma; ZI-KL1-1 which is in preclinical trial for the treatment of breast, gastric, lung, pancreatic, and cervix cancers; and ZI-PR-1 which is in discovery stage for the treatment of solid tumors. The company was incorporated in 2016 and is headquartered in Oslo, Norway.

zelluna.com

15

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 11/2/2026, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) .

YTD Return

ZLNA.OL
24.64%
MSCI WORLD (^990100-USD-STRD)
9.01%

1-Year Return

ZLNA.OL
56.36%
MSCI WORLD (^990100-USD-STRD)
10.69%

3-Year Return

ZLNA.OL
98.28%
MSCI WORLD (^990100-USD-STRD)
73.72%

5-Year Return

ZLNA.OL
98.65%
MSCI WORLD (^990100-USD-STRD)
52.32%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -59.97%

  • Return on Equity (ttm)

    -115.40%

  • Revenue (ttm)

    8k

  • Net Income Avi to Common (ttm)

    -114.8M

  • Diluted EPS (ttm)

    -4.90

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    86.24M

  • Total Debt/Equity (mrq)

    1.00%

  • Levered Free Cash Flow (ttm)

    -62.65M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: